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Mutation in the LMNA gene, encoding lamin A/C, causes a diverse group of diseases called laminopathies. Cardiac
involvement is the major cause of death and manifests as dilated cardiomyopathy, heart failure, arrhythmias, and sudden
death. There is no specific therapy for LMNA-associated cardiomyopathy. We report that deletion of Lmna in
cardiomyocytes in mice leads to severe cardiac dysfunction, conduction defect, ventricular arrhythmias, fibrosis,
apoptosis, and premature death within 4 weeks. The phenotype is similar to LMNA-associated cardiomyopathy in
humans. RNA sequencing, performed before the onset of cardiac dysfunction, led to identification of 2338 differentially
expressed genes (DEGs) in Lmna-deleted cardiomyocytes. DEGs predicted activation of bromodomain-containing protein
4 (BRD4), a regulator of chromatin-associated proteins and transcription factors, which was confirmed by complementary
approaches, including chromatin immunoprecipitation sequencing. Daily injection of JQ1, a specific BET bromodomain
inhibitor, partially reversed the DEGs, including those encoding secretome; improved cardiac function; abrogated cardiac
arrhythmias, fibrosis, and apoptosis; and prolonged the median survival time 2-fold in the myocyte-specific Lmna-deleted
mice. The findings highlight the important role of LMNA in cardiomyocytes and identify BET bromodomain inhibition as a
potential therapeutic target in LMNA-associated cardiomyopathy, for which there is no specific effective therapy.
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Introduction
Heart failure is a major cause of morbidity and mortality in the 
world (1, 2). It affects an estimated 26 million people worldwide 
and more than 10% of the elderly in the Western world (1–3). Prev-
alence of heart failure continues to rise. An estimated 6.2 million 
Americans older than 20 years had heart failure between 2013 
and 2016 (2.6% of the population) as compared with 5.7 million 
between 2009 and 2012 (1). Heart failure remains the number one 
cause of hospitalization in the United States and Europe (3).
Dilated cardiomyopathy (DCM), characterized by an 
increased left ventricular end-diastolic diameter (LVEDD) and a 
reduced left ventricular ejection fraction, is a major cause of heart 
failure and the most common indication for cardiac transplanta-
tion (4–6). DCM is a heterogeneous disease with several etiolo-
gies. Primary DCM is a genetic disease of the myocardium that 
typically exhibits an autosomal dominant pattern of inheritance. 
It is caused primarily by mutations in genes coding for sarcomere 
and cytoskeletal proteins (4, 7). Mutations in the LMNA gene, 
encoding the nuclear envelope protein lamin A/C (LMNA), are the 
second most common cause of DCM, accounting for up to 10% of 
familial DCM (8, 9).
Mutations in the LMNA gene cause a diverse array of diseases 
referred to as laminopathies, including DCM, which is a common 
manifestation (10–13). DCM caused by LMNA mutations (hence-
forth LMNA-DCM) is the major cause of premature death in lam-
inopathies (11, 12, 14). LMNA-DCM has a phenotypic expression 
that is somewhat distinct from DCM caused by mutations in genes 
encoding sarcomere and cytoskeletal protein, because of a high 
prevalence of cardiac conduction defects, arrhythmias, and sud-
den cardiac death (8, 9, 11, 14–18). LMNA mutations are responsible 
for about a third of DCM cases associated with cardiac conduction 
defects (8). Given the poor prognosis and the high risk of sudden 
cardiac death, the presence of LMNA pathogenic variants typically 
necessitates implantation of a defibrillator (11, 12, 15, 18–20).
Despite the clinical significance of LMNA-DCM, there is no 
specific treatment for this potentially deadly form of heart failure, 
likely because of our inadequate understanding of its molecu-
lar pathogenesis. We and others have recently implicated dou-
ble-stranded DNA breaks and consequent activation of the DNA 
damage response pathway as an upstream mechanism that insti-
gates induction of phenotype, composed of inflammation, apopto-
sis, cell senescence, fibrosis, cardiac dysfunction, and premature 
death, in humans and mouse models of LMNA-DCM as well as 
in other laminopathies (21–25). Several downstream pathways, 
including TP53, FOXO3, PDGFRB, and MAPK, are also implicat-
ed in the pathogenesis of LMNA-DCM, illustrating the complexity 
of the disease (13, 26–28).
LMNA is a ubiquitously expressed protein constituent of 
nuclear inner membrane with low cell type or tissue specificity 
(13, 29). However, LMNA interacts with chromatin through lamin- 
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Gross morphology. Myh6-Cre LmnaW/F and Myh6-Cre LmnaF/F 
mice had normal growth rates for the first 3 weeks of life, but the 
Myh6-Cre LmnaF/F mice showed stunted growth after 3 weeks of 
life, as indicated by failure to gain weight (Supplemental Figure 2). 
At 4 weeks of age, the Myh6-Cre LmnaF/F mice had a 40.2% ± 2.1% 
lower body weight as compared with the WT mice. The LmnaF/F, 
Myh6-Cre, and Myh6-Cre LmnaW/F mice had a normal growth 
curve during this period (Supplemental Figure 2).
Survival. The Myh6-Cre LmnaF/F mice showed increased mor-
tality, notably starting at 3 weeks of age and rapidly progressing 
to 100% mortality by 4 weeks (Figure 1F). The Myh6-Cre LmnaW/F 
mice also exhibited an increased mortality albeit at an older age, 
reaching 100% mortality by 15 months of age (Figure 1F and 
inset). The median survival time in Myh6-Cre LmnaF/F was 22 days, 
whereas it was about 8 months in the Myh6-Cre LmnaW/F mice 
(Figure 1F and inset). WT, LmnaF/F, and Myh6-Cre had normal 
survival (Figure 1F). The survival rates between male and female 
Myh6-Cre LmnaF/F were similar (Supplemental Figure 3).
Cardiac function. The Myh6-Cre LmnaF/F mice exhibited car-
diac dilatation and systolic dysfunction, as indicated by a mark-
edly increased LVEDD and left ventricular end-systolic diame-
ter (LVESD), and reduced left ventricular fractional shortening 
(LVFS) at 3 weeks of age compared with WT mice (Figure 2A and 
Supplemental Table 1). The heterozygous Lmna-deficient mice 
had normal cardiac function at 3 weeks of age (Supplemental 
Table 1). However, these mice developed cardiac dilatation and 
dysfunction at 10 months of age, the last time point analyzed (Sup-
plemental Table 2). The Myh6-Cre and LmnaF/F mice, which were 
included as control, did not show evidence of cardiac dysfunction 
compared with WT mice (Supplemental Tables 1 and 2). There was 
no sex-dependent effect on indices of cardiac function in Myh6-
Cre LmnaF/F mice, as both sexes showed significant cardiac dys-
function at 3 weeks of age (Supplemental Figure 4).
Cardiac arrhythmias. Myh6-Cre LmnaW/F and Myh6-Cre 
LmnaF/F mice showed sinus bradyarrhythmias; atrial flutter; atrio-
ventricular blocks, including complete heart block; ectopic ven-
tricular beats; and ventricular tachycardia, all occurring within the 
first 3 weeks in the Myh6-Cre LmnaF/F mice and at an older age in 
the Myh6-Cre LmnaW/F mice (Figure 2B and Supplemental Tables 3 
and 4). Advanced atrioventricular block (second and third degree) 
was common and was observed in approximately two-thirds of the 
3-week-old Myh6-Cre LmnaF/F mice. Likewise, ventricular tachy-
cardia (≥3 ventricular ectopic beats in a row with a rate of >300 
bpm) was recorded in about 20% of the Myh6-Cre LmnaF/F mice 
(Supplemental Table 3). WT, LmnaF/F, and Myh6-Cre mice did not 
exhibit notable cardiac arrhythmias, except for premature atrial 
and ventricular contractions (Supplemental Tables 3 and 4).
Myocardial fibrosis and apoptosis. Collagen volume fraction 
(CVF), a measure of myocardial fibrosis, was increased about 
8-fold in 3-week-old Myh6-Cre LmnaF/F as compared with WT 
mice (Figure 2, C–E). Likewise, the number of TUNEL-positive 
cells was increased about 10-fold (Figure 2, F and G).
The heterozygous Lmna-knockout mice did not exhibit signifi-
cant myocardial fibrosis or apoptosis at 3 weeks of age but showed 
4-fold increased myocardial fibrosis and approximately 7-fold 
increased apoptosis as compared with corresponding WT mice at 
10 months of age (Supplemental Figure 5). The LmnaF/F mice did 
associated domains (LADs) and influences gene expression in 
a cell type–specific manner (30–33). In human cardiomyocytes, 
LMNA interacts with chromatin in about 300 genomic regions, 
each approximately 2 million to 3 million bases in length, which 
collectively comprise about 20% of the genome (31). Cell type–
invariant (constitutive) LADs encompass a minority of the LADs, 
whereas the majority are facultative and cell type–specific (30–33). 
Therefore, cell type–specific interventions in the heart are expect-
ed to provide insights into the specific role of each cardiac cell 
type in the pathogenesis of LMNA-DCM and raise the prospect 
of therapeutic opportunities. Accordingly, we deleted the mouse 
Lmna gene specifically in cardiomyocytes, the main cell type in 
the heart, characterized the phenotype, and identified the major 
dysregulated pathways. Deletion of Lmna in cardiomyocytes was 
associated with activation of bromodomain-containing protein 4 
(BRD4). Pharmacological targeting of BET bromodomain proteins 
by JQ1 partially restored dysregulated gene expression, including 
genes encoding secretome, and improved survival, cardiac func-
tion, myocardial fibrosis, and apoptosis in the myocyte-specific 
Lmna-knockout mouse model of LMNA-DCM. The findings raise 
the prospect of interventions targeting BET bromodomain pro-
teins for therapeutic gain in LMNA-DCM.
Results
Cardiomyocyte-specific deletion of Lmna in mice. The Lmna gene 
was deleted in cardiomyocytes by crossing of LmnaF/F and 
Myh6-Cre deleter mice (34, 35). Heterozygous and homozygous 
Lmna-knockout mice were born per the expected Mendelian ratio 
and did not show discernible phenotype at birth. To determine 
efficiency of deletion of the Lmna gene in cardiomyocytes, thin 
myocardial sections from WT, Myh6-Cre LmnaW/F, and Myh6-Cre 
LmnaF/F mouse hearts were costained with antibodies against 
LMNA and pericentriolar membrane-1 (PCM1), which tags car-
diomyocyte nuclei in the heart (36–38). PCM1 expression was 
detected in approximately a third of the cells in the myocardi-
um (Figure 1, A and B). PCM1-expressing cells also stained pos-
itive for expression of LMNA in the WT and Myh6-Cre LmnaW/F 
mouse hearts (Figure 1, A–C). In contrast, only 0.52% ± 0.4% of 
PCM1-expressing cells, i.e., myocytes, stained positive for LMNA 
expression in the Myh6-Cre LmnaF/F mouse hearts, indicating a 
near-complete absence of the LMNA protein in cardiomyocytes 
(Figure 1, A–C). To further validate the findings, immunoblotting, 
using an anti-LMNA antibody, was performed on protein extracts 
from cardiomyocytes isolated from WT, Myh6-Cre LmnaW/F, 
and Myh6-Cre LmnaF/F mice. The LMNA protein was reduced in 
Myh6-Cre LmnaW/F and was almost completely absent in Myh6-
Cre LmnaF/F myocytes, as compared with WT myocytes (Figure 1, 
D and E). These findings supported efficient deletion of the Lmna 
gene in cardiomyocytes. Expression levels of the LMNA protein 
in cardiomyocyte extracts from mice carrying the loxP sequences 
flanking exon 2 of the Lmna gene (LmnaF/F) were similar to those 
in the WT mice (Supplemental Figure 1, A and B; supplemental 
material available online with this article; https://doi.org/10.1172/
JCI135922DS1). Likewise, immunoblotting of protein extracts 
from the noncardiomyocyte cells in the heart showed unaltered 
LMNA protein levels in the Myh6-Cre LmnaF/F mice (Supplemental 
Figure 1, C and D).
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Figure 1. Conditional deletion of Lmna gene in cardiomyocytes in mice. (A) Representative immunofluorescence staining of thin myocardial section from 
3-week-old WT, Myh6-Cre LmnaW/F, and Myh6-Cre LmnaF/F mice showing localization of LMNA (red) at the nuclear membrane in PCM1-labeled (green) 
cardiomyocytes. Nuclei were counterstained with DAPI (blue). Scale bars: 20 μm, 10 μm (insets). (B) Quantitative data of PCM1-labeled nuclei in WT (n = 3), 
Myh6-Cre LmnaW/F (n = 4), and Myh6-Cre LmnaF/F (n = 5, P = 0.95). (C) Quantitative data of PCM1-labeled nuclei showing expression of LMNA in WT, Myh6-
Cre LmnaW/F, and Myh6-Cre LmnaF/F (n = 5, P < 0.0001). (D) Western blots showing expression of LMNA in isolated cardiomyocyte cell lysates in 2-week-
old WT, Myh6-Cre LmnaW/F, and Myh6-Cre LmnaF/F and the corresponding GAPDH as a loading control. (E) Quantitative data on LMNA expression levels 
in cardiomyocytes in WT (n = 6), Myh6-Cre LmnaW/F (n = 6), and Myh6-Cre LmnaF/F mice (n = 6, P = 0.0017). (F) Kaplan-Meier curve showing the survival 
of WT (n = 52), Myh6-Cre (n = 38), LmnaF/F (n = 50), Myh6-Cre LmnaW/F (n = 40), and Myh6-Cre LmnaF/F (n = 37) mice during the first 4 weeks (χ2 = 231, P < 
0.0001) and 16 months (inset; χ2 = 344, P < 0.0001) after birth. P values shown in B, C, and E were calculated by 1-way ANOVA followed by Tukey’s post hoc 
pairwise comparison test.
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Figure 2. Cardiac phenotype in 3-week-old WT, Myh6-Cre LmnaW/F, and Myh6-Cre LmnaF/F mice. (A) Selected echocardiographic parameters showing 
left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), left ventricular end-systolic diameter indexed to body 
weight (LVESDi), left ventricular fractional shortening (LVFS), and left ventricular mass indexed to body weight (LVMi) in 3-week-old WT (n = 13), Myh6-
Cre LmnaW/F (n = 12), and Myh6-Cre LmnaF/F (n = 17) mice. P values shown were obtained using ordinary 1-way ANOVA and Bonferroni’s post hoc test for 
comparisons of the LVEDD, LVESDi, and LVMi, and Kruskal-Wallis and Dunn’s post hoc test for comparisons for LVESD and LVFS. (B) Selected representa-
tive surface ECG recordings showing third-degree atrioventricular block (no association between P and QRS waves) and ventricular tachycardia observed in 
the Myh6-Cre LmnaW/F (n = 19) and Myh6-Cre LmnaF/F mice (n = 19). (C and D) Masson’s trichrome–stained (top panel) and Picrosirius red–stained (bottom 
panel) representative myocardial sections in 3-week-old WT, Myh6-Cre LmnaW/F, and Myh6-Cre LmnaF/F mice. (E) Corresponding quantitative data on 
percentage collagen volume fraction (CVF) in myocardial sections in the WT (n = 4), Myh6-Cre LmnaW/F (n = 5), and Myh6-Cre LmnaF/F (n = 7) mice. (F) 
TUNEL-stained thin myocardial sections in 3-week-old WT, Myh6-Cre LmnaW/F, and Myh6-Cre LmnaF/F mice. TUNEL-positive cells are shown in green and 
nuclei, counterstained with DAPI, in blue. (G) Quantitative data showing percentage of TUNEL-positive nuclei in the WT (n = 5), Myh6-Cre LmnaW/F (n = 5), 
and Myh6-Cre LmnaF/F (n = 6) mice. P values shown in E and G were calculated using ordinary 1-way ANOVA and Tukey’s post hoc test.
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activation of EMT in the heart and the prominent expression of 
myocardial fibrosis in Myh6-Cre LmnaF/F hearts, rendering BRD4 
a potential therapeutic target. To strengthen the evidence for 
activation of BRD4, DEGs in the Myh6-Cre LmnaF/F cardiomyo-
cytes were analyzed against 3 publicly available mouse heart and 
1 rat cardiomyocyte RNA-Seq data sets with defined BRD4 tar-
gets (39–41). BRD4 targets in each data set were defined as genes 
whose transcript levels were increased in the pathological state 
(including intervention) but were reduced subsequently upon inhi-
bition of BRDs or BRD4. As shown in the GSEA plots in Figure 4A, 
BRD4 target genes, identified in 4 publicly available data sets, were 
enriched in Myh6-Cre LmnaF/F cardiomyocytes. Similarly, DEGs 
in Myh6-Cre LmnaF/F cardiomyocytes were also enriched for the 
BRD4 target genes gathered from the IPA data sets (Figure 4B). 
Transcript levels of the BRD4 target genes, identified in all 4 data 
sets and from the IPA database, in the Myh6-Cre LmnaF/F cardiomy-
ocytes are depicted in a heatmap (Figure 4C). As shown, transcript 
levels of 123 BRD4 target genes were upregulated in the Myh6-Cre 
LmnaF/F cardiomyocytes as compared with WT myocytes, whereas 
expression of 17 genes was suppressed (P < 0.0001; Figure 4C).
To determine whether increased transcript levels of BRD4 
were because of increased BRD4 protein levels, immunoblotting 
was performed on cardiomyocyte protein extracts from the WT 
and Myh6-Cre LmnaF/F mice. There was no difference in the BRD4 
protein levels between the 2 groups (Supplemental Figure 10). 
Likewise, BRD2 and BRD3 protein levels were unchanged (Sup-
plemental Figure 10).
BRD4 ChIP-Seq. To determine whether increased transcript 
levels of BRD4 target genes in the Myh6-Cre LmnaF/F cardiomy-
ocytes were because of increased recruitment of BRD4 to chro-
matin, BRD4 ChIP-Seq was performed on myocyte chromatin 
extracts using an anti-BRD4 antibody. Representative Integra-
tive Genomics Viewer (IGV) tracks showing BRD4 enrichment in 
the corresponding regions in the Myh6-Cre LmnaF/F myocytes are 
shown (Figure 5A). The total number of peaks in each ChIP-Seq 
experiment and the intersects showing shared peaks between the 
samples in each genotype are presented in the Venn diagrams in 
Supplemental Figure 11A. BRD4 ChIP peaks were redistribut-
ed in the Myh6-Cre LmnaF/F as compared with WT cardiomyo-
cyte genomes, as only about 10,776 of 44,947 (24%) of the peaks 
were shared between the 2 genotypes (Supplemental Figure 11B). 
Approximately 6000 BRD4-enriched peaks were overlapped in at 
least 2 genomes in the WT or Myh6-Cre LmnaF/F myocytes, of which 
758 (12.6%) were exclusive to WT, and 1946 (32.4%) to Myh6-Cre 
LmnaF/F genomes (Supplemental Figure 11C). Distributions of 
BRD4 ChIP-Seq peaks differed in their localizations to genomic 
partitions between the WT and Myh6-Cre LmnaF/F myocytes, as 
more peaks were located in the upstream (P = 0.0007) and down-
stream (P < 0.0001) genomic regions in the Myh6-Cre LmnaF/F 
genomes (Supplemental Figure 11D).
To validate the BRD4 ChIP-Seq findings, ChIP was performed 
on an independent set of chromatin extracts from the WT and 
Myh6-Cre LmnaF/F myocytes. The chromatin precipitates were ana-
lyzed for the enrichment of the genomic DNA mapped to the peak 
regions in the discovery ChIP-Seq experiments. As shown in Fig-
ure 5, A and B, genomic DNA located at the BRD4 ChIP-Seq peaks 
were enriched in both WT and Myh6-Cre LmnaF/F myocytes in the 
not show evidence of myocardial fibrosis, as percentage CVF was 
similar to that in the WT mice (Supplemental Figure 6).
Differentially expressed genes in cardiomyocytes isolated from 
Myh6-Cre LmnaF/F mouse hearts. To identify transcriptomic chang-
es in cardiomyocytes that are consequent to deletion of the Lmna 
gene but precede the onset of cardiac dysfunction, cardiac pheno-
type was assessed in 2-week-old mice. There was no discernible 
evidence of cardiac dysfunction on echocardiogram at 2 weeks of 
age (Supplemental Table 5). Likewise, CVF was not significantly 
different between the WT and Myh6-Cre LmnaF/F mice, and the 
number of TUNEL-positive cells was also similar between the 2 
genotypes (Supplemental Figure 7). Therefore, cardiomyocytes 
were isolated from 2-week-old WT and Myh6-Cre LmnaF/F mice to 
extract RNA for RNA-Seq.
Principal component analysis of the RNA-Seq data showed 
segregation of the samples according to the mouse genotype 
(Supplemental Figure 8). A total of 2338 genes were differential-
ly expressed in the Myh6-Cre LmnaF/F as compared with WT car-
diomyocytes, of which 1419 genes were downregulated, whereas 
transcript levels of 919 genes were increased (Figure 3A). Unsu-
pervised hierarchical clustering showed distinct grouping of the 
samples per genotypes (Figure 3B).
Ingenuity Pathway Analysis (IPA) of differentially expressed 
genes (DEGs) predicted activation of the transcriptional regula-
tors lysine demethylase 5A (KDM5A), TP53, mitogen-activated 
protein kinase 4 (MAP4K4), nuclear receptor–interacting pro-
tein 1 (NRIP1), BRD4, and ERG1 in the Myh6-Cre LmnaF/F mouse 
cardiomyocytes (Figure 3C). In contrast, retinoblastoma 1 (RB1), 
insulin receptor (INSR), and peroxisome proliferator–activated 
receptor-γ coactivator 1α (PPARGC1α) were predicted to be sup-
pressed (Figure 3D).
Gene set enrichment analysis (GSEA) of DEGs against Molec-
ular Signatures Database hallmark gene sets identified enrich-
ment for genes involved in epithelial-mesenchymal transition 
(EMT), inflammation, and apoptosis (Figure 3E), whereas genes 
involved in oxidative phosphorylation, metabolism, and myogen-
esis were underrepresented (Figure 3F).
The DEGs were analyzed to identify genes whose protein 
products are known to be or expected to be secreted, i.e., the secre-
tome. A total of 168 of 2338 DEGs (7.2%) coded for secretome, 
which are depicted in a heatmap in Supplemental Figure 9A. To 
validate the RNA-Seq data, quantitative reverse transcriptase PCR 
(RT-qPCR) was performed, which showed changes concordant 
with the RNA-Seq findings for 17 of 18 genes tested (13 increased 
and 4 decreased), and 1 gene was unchanged (Supplemental Fig-
ure 9, B and C). DEGs coding for secretome predicted TGF-β1 as 
the most activated and α-catenin as the most suppressed regula-
tors of gene expression (Supplemental Figure 9D). A GSEA plot 
showing enrichment of genes in the TGF-β1 pathway is illustrat-
ed in Supplemental Figure 9E. Immunoblotting of cardiomyocyte 
extracts suggested increased levels of the active TGF-β1 protein in 
the Myh6-Cre LmnaF/F cardiomyocytes (Supplemental Figure 9, F 
and G). In accord with activation of TGF-β1, the DEGs encoding 
secretome were involved in EMT, angiogenesis, STAT signaling, 
hypoxia, and apoptosis (Supplemental Figure 9H).
Activation of BRD4 in Myh6-Cre LmnaF/F cardiomyocytes. Pre-
dicted activation of BRD4 based on the DEGs was in accord with 
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Figure 3. Differentially expressed genes in 2-week-old WT and Myh6-Cre LmnaF/F mouse cardiomyocytes. (A) Volcano plot depicting differentially 
expressed genes (DEGs) showing downregulation of 1419 and upregulation of 919 genes in Myh6-Cre LmnaF/F (n = 6) compared with WT mouse cardiomy-
ocytes (n = 6). (B) Heatmap and unsupervised hierarchical clustering of the DEGs in WT and Myh6-Cre LmnaF/F mouse cardiomyocytes, showing clustering 
according to the genotype. (C and D) Ingenuity Pathway Analysis (IPA) for inferred activated (C) and suppressed (D) upstream regulators of the DEGs in 
Myh6-Cre LmnaF/F mouse cardiomyocytes. Z score and percentage of overlap of the DEGs with the IPA database are depicted on the graphs. The size of 
each circle is proportional to the percentage of genes considered as downstream targets of each regulator in the RNA-Seq data set. (E and F) Top signifi-
cantly enriched hallmark pathways activated (E) or inhibited (F), inferred using Gene Set Enrichment Analysis (GSEA). Normalized enrichment score (NES) 
and number of genes involved (size of the circle) are depicted for each pathway.
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development and myocyte maturation/proliferation in the ear-
ly postnatal stage (45–47). Consequently, a series of time course 
studies were performed in the WT mice to determine the effects 
of injection of JQ1 at the commonly used dose of 50 mg/kg/d of 
JQ1 at postnatal day 4 (P4), P7, P10, and P14 on survival and body 
growth (42, 44). JQ1 administration at 50 mg/kg/d was associated 
with increased mortality, growth retardation, and alopecia at the 
injection site, which were more pronounced when JQ1 was inject-
ed at earlier rather than later time points (Supplemental Figure 13). 
Injection of JQ1 at a later time point (after P14) was not considered 
because of the potential confounding effects of early mortality of 
the Myh6-Cre LmnaF/F mice. Therefore, the JQ1 dose was reduced 
to 20 mg/kg/d, which has been shown to effectively inhibit BET 
bromodomain protein activity (48, 49). JQ1 administered at 20 
mg/kg/d did not affect survival or gain in weight in the WT mice 
(Supplemental Figure 14). Consequently, the subsequent experi-
ments in WT and Myh6-Cre LmnaF/F mice were performed with 20 
mg/kg/d injected subcutaneously beginning at P14.
Effects of JQ1 on cardiomyocyte transcripts and regulatory path-
way. RNA was extracted from cardiomyocytes isolated from 
3-week-old WT mice, Myh6-Cre LmnaF/F mice treated with a 
vehicle, and Myh6-Cre LmnaF/F mice treated with JQ1 (20 mg/
kg/d) for 1 week (P14 to P21). Gene expression was analyzed by 
RNA-Seq. Treatment with JQ1 shifted the transcriptomic profile 
of the cardiomyocytes toward that of the WT, as illustrated in the 
heatmap (Figure 6A). Overall, a total of 1817 genes were differen-
tially expressed between the WT and Myh6-Cre LmnaF/F myocytes. 
Treatment with JQ1 normalized transcript levels of 152 genes (no 
difference between JQ1-treated Myh6-Cre LmnaF/F and WT myo-
cytes) and significantly lowered transcript levels of another 410 
genes (Figure 6B). Overall, transcript levels of 562 DEGs (31%) 
had reversed toward normal (Figure 6B). To determine efficacy of 
treatment with JQ1 in suppressing BRD4 activity, transcript levels 
of the BRD4 target genes in the untreated and JQ1-treated Myh6-
Cre LmnaF/F myocytes were compared. GSEA showed suppression 
of the BRD4 target gene transcript levels in the JQ1-treated myo-
cytes as compared with untreated Myh6-Cre LmnaF/F myocytes 
(Figure 6, C and D).
To validate the RNA-Seq data, transcript levels of 32 BRD4 
target genes were quantified by RT-qPCR in cardiomyocyte RNA 
extracts from the WT mice, Myh6-Cre LmnaF/F mice treated with 
a vehicle (10% DMSO and 10% 2-hydroxypropyl-β-cyclodextrin), 
and Myh6-Cre LmnaF/F mice treated with JQ1 (20 mg/kg/d for 7 
days, starting at P14). Treatment with JQ1 normalized elevated tran-
script levels of 15 of 30 selected BRD4 target genes and significantly 
reduced, but did not normalize, levels of another 7 target genes (Fig-
ure 6E and Supplemental Figure 15A). JQ1 treatment had no effect 
on transcript levels of 9 selected DEGs, whereas the transcript level 
of 1 candidate target gene was similar among the 3 groups, i.e., not 
differentially expressed (Supplemental Figure 15B).
Genes whose transcript levels were significantly affected by 
JQ1 treatment were analyzed by IPA to infer the transcriptional 
regulators. The approach predicted activation of over a dozen reg-
ulators of gene expression, including TGF-β1, STAT1, and RELA 
(Figure 7, A and B). A complete list of dysregulated growth/para-
crine factors and transcriptional regulators is provided in Supple-
mental Table 6. Biologically, genes regulated by JQ1 were involved 
independent validation ChIP experiments, albeit the enrichment 
was greater in the Myh6-Cre LmnaF/F than in the WT myocytes.
To determine whether recruitment of BRD4 to chromatin 
affected gene expression in the Myh6-Cre LmnaF/F myocytes, tran-
script levels of the annotated genes located in the BRD4 peak and 
outside of the peak regions were compared. Globally, transcript 
levels of genes located at the peak regions were higher as com-
pared with those located outside of the peak regions (Figure 5C). 
Representative genome browser tracks of the transcript levels at 
the peak regions as compared with regions outside of peaks are 
shown in Supplemental Figure 12A. Likewise, gain of peak (GoP), 
defined as peak present in the Myh6-Cre LmnaF/F and absent in 
the WT, was associated with a greater number of genes (a high-
er gene density) that were upregulated, as compared with loss of 
peak (LoP), defined as peaks absent in the Myh6-Cre LmnaF/F but 
present in the WT myocytes (Supplemental Figure 12B). Likewise, 
a greater number of DEGs located at the GoP regions were upreg-
ulated as compared with DEGs located at the LoP regions (Figure 
5C and Supplemental Figure 12B). The difference in the gene den-
sity was also remarkable for the upregulated DEGs located at the 
upstream genomic regions (Supplemental Figure 12C).
Given the differences in genomic partition of BRD4 peaks, 
distribution of the annotated DEGs in each genomic segment 
was compared between the WT and Myh6-Cre LmnaF/F myocytes 
(Supplemental Figure 12D). Only distribution of DEGs located 
in the upstream genomic regions differed significantly between 
the WT and Myh6-Cre LmnaF/F myocytes (Supplemental Figure 
12D). Finally, LoP in the Myh6-Cre LmnaF/F genome was asso-
ciated with a larger number of DEGs located in the upstream 
region (39/54; 72%) whose expression levels were suppressed 
(Supplemental Figure 12E).
Dose titration studies with JQ1. Given the data indicating acti-
vation of BDR4 in the Myh6-Cre LmnaF/F myocytes, phenotypic 
effects of pharmacological BET bromodomain inhibition were 
analyzed in the Myh6-Cre LmnaF/F mice. The primary endpoint 
was survival, and the secondary endpoints were myocardial func-
tion and fibrosis. The latter was selected based on evidence of 
enrichment of the DEGs for EMT, presence of myocardial fibro-
sis in Myh6-Cre LmnaF/F hearts, and the prominent antifibrotic 
effects of BRD4 (41–43).
JQ1, a well-established specific paninhibitor of BET bromo-
domain proteins, was selected to treat the Myh6-Cre LmnaF/F mice 
(44). The 3- to 4-week life span of the Myh6-Cre LmnaF/F mice 
necessitated administration of JQ1 at a very young age, which was 
counterbalanced by potential fortuitous effects arising because 
of the prominent role of epigenetic regulation during cardiac 
Figure 4. Evidence of BET bromodomain activation in Myh6-Cre LmnaF/F 
mouse cardiomyocytes. (A) GSEA plot of DEGs in Myh6-Cre LmnaF/F 
mouse cardiomyocytes against predicted BRD target genes gathered from 
whole mouse heart after transaortic constriction or myocardial infarction 
(GSE96561, GSE96561, and GSE48110) and in rat neonatal ventricular car-
diomyocytes (NVRM; GSE83228). (B) GSEA of DEGs in Myh6-Cre LmnaF/F 
mouse cardiomyocytes against predicted BRD target genes obtained from 
IPA. (C) Heatmap and unsupervised hierarchical clustering of 145 DEGs in 
Myh6-Cre LmnaF/F mouse cardiomyocytes obtained after overlapping with 
the GSEA data shown in A and B.
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The RNA-Seq data were also analyzed for the effects of treat-
ment with JQ1 on expression levels of genes encoding secreted 
proteins (secretome). Treatment with JQ1 shifted the secretome 
profile of the Myh6-Cre LmnaF/F toward that of the WT myocytes, 
in EMT and innate immune response, among other functions (Fig-
ure 7C). Concordant with this finding, GSEA showed activation of 
the EMT pathway in Myh6-Cre LmnaF/F mice and its reversal upon 
treatment with JQ1 (Figure 7, D and E).
Figure 5. BRD4 activation in Myh6-Cre LmnaF/F mouse cardiomyocytes. (A) ChIP-qPCR in WT and Myh6-Cre LmnaF/F mouse cardiomyocyte chroma-
tin extracts (n = 2 for each genotype) and IGV tracks from ChIP-Seq showing BRD4 enrichment in the corresponding regions assessed. (B) Violin plots 
depicting transcript levels of all genes at nonpeak and BRD4 peak regions in Myh6-Cre LmnaF/F mouse cardiomyocytes (P < 0.0001 by Kruskal-Wallis). (C) 
Transcript levels of DEGs plotted against gene density at the GoP and LoP genomic regions, showing a higher density of genes with increased transcript 
levels in the GoP regions.
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Figure 6. Effect of BET bromodomain inhibition on the transcriptome of Myh6-Cre LmnaF/F mouse cardiomyocytes. (A) Heatmap of the DEGs in WT, 
Myh6-Cre LmnaF/F, and JQ1-treated Myh6-Cre LmnaF/F mouse cardiomyocytes (n = 4 for each). (B) Pie chart depicting the number of genes that were 
rescued and partially rescued upon JQ1 treatment in Myh6-Cre LmnaF/F mouse cardiomyocytes from the differentially expressed genes between WT and 
Myh6-Cre LmnaF/F myocytes. (C and D) GSEA plots of the BRD4 target genes showing induction in Myh6-Cre LmnaF/F compared with WT cardiomyocytes 
(NES = 2.89, q < 0.0001) (C), and partial suppression in JQ1-treated Myh6-Cre LmnaF/F compared with Myh6-Cre LmnaF/F (NES = –1.46, q = 0.09) (D). (E) 
RT-qPCR data showing transcript levels of selected BRD4 target genes in WT (n = 6), untreated (n = 6), and JQ1-treated Myh6-Cre LmnaF/F mouse cardiomy-
ocytes (n = 7). P values were obtained with ordinary 1-way ANOVA or Kruskal-Wallis; *P < 0.05, †P < 0.01, #P < 0.001, ‡P < 0.0001.
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Figure 7. Upstream regulators and biological pathways altered after BET bromodomain inhibition in Myh6-Cre LmnaF/F mouse cardiomyocytes. (A and 
B) Major putative inferred upstream regulators and their targets from IPA overlap analysis of the completely and partially rescued genes upon JQ1 treat-
ment in Myh6-Cre LmnaF/F. (C) Circos plot showing the top significantly enriched hallmark pathways inferred from the completely and partially rescued 
genes upon JQ1 treatment in Myh6-Cre LmnaF/F using GSEA, with the log2 fold change depicting the relative expression of the genes involved in these 
pathways: (I) Myh6-Cre LmnaF/F compared with WT cardiomyocytes; (II) JQ1-treated Myh6-Cre LmnaF/F compared with Myh6-Cre LmnaF/F. (D and E) GSEA 
plots of EMT showing induction in Myh6-Cre LmnaF/F compared with WT cardiomyocytes (NES = 2.3, q < 0.0001) (D), and partial suppression in JQ1-treated 
Myh6-Cre LmnaF/F compared with Myh6-Cre LmnaF/F (NES = –1.14, q = 0.43) (E).
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mice (Supplemental Figure 17). Myh6-Cre LmnaF/F mice, regard-
less of the treatment groups, had a smaller body weight after 3 
weeks of age as compared with the WT mice.
Effects of JQ1 on cardiac function. WT and Myh6-Cre LmnaF/F 
mice were treated with a vehicle or JQ1 at 20 mg/kg/d starting at 
P14, and cardiac size and function were assessed by echocardiog-
raphy at 3 weeks of age. Treatment with JQ1 improved left ventric-
ular size and function in the Myh6-Cre LmnaF/F mice, as indicated 
by a smaller LVEDD and LVESD, improved LVFS, and reduced left 
ventricular mass (Table 1 and Figure 8B). Genotype-by-treatment 
interaction analysis showed significant effects of the genotype 
alone, treatment alone, and genotype-by-treatment interactions 
on the LVFS (Table 1). Treatment with JQ1 did not have a discern-
ible effect on echocardiographic indices of cardiac size and func-
tion in the WT mice (Table 1).
Effects of JQ1 on molecular markers of cardiac dysfunction. Cardiac 
hypertrophy and failure are associated with changes in expression 
of a number of genes referred to as markers of cardiac hypertrophy 
and dysfunction, including Nppa, Nppb, Myh6, Myh7, Atp2a2, and 
Actc1 (50–52). To corroborate the beneficial effects of JQ1 on sur-
vival and cardiac function, transcript levels of the molecular mark-
ers of cardiac dysfunction were quantified by RT-qPCR on cardiac 
RNA extracts. Transcript levels of Nppa, Nppb, Myh7, and Actc1 were 
increased and those of Atp2a2 and Myh6 were reduced in the Myh6-
Cre LmnaF/F hearts, which was in accord with the anticipated chang-
es in cardiac hypertrophy and failure (50–52). Treatment with JQ1 
completely or partially rescued transcript levels of the molecular 
markers of cardiac hypertrophy and dysfunction (Figure 8C).
Effects of JQ1 on cardiac arrhythmias. Phenotypic characteris-
tics of human LMNA-DCM include conduction defects and ven-
involving 195 genes, as depicted in the heatmap shown in Supple-
mental Figure 16A. Treatment with JQ1 normalized transcript lev-
els of 21 genes encoding secretome and significantly reduced tran-
script levels of another 50 genes, albeit the latter group was not 
normalized (Supplemental Figure 16B). The findings were tested 
for validation by RT-qPCR, which was in agreement with the RNA-
Seq data, as transcript levels of 11 of 12 upregulated genes (92%) 
were either normalized or partially reduced (Supplemental Figure 
16C). Analysis of the DEGs encoding secretome predicted acti-
vation of several growth and paracrine factors, including GDF15, 
TGF-β1, and FGF21 among others, which might contribute to the 
pathogenesis of the phenotype (Supplemental Figure 16D). The 
findings of a similar analysis to predict transcriptional regulators 
of secretome are presented in Supplemental Figure 16E. Finally, 
genes encoding secretome were mostly involved in extracellular 
matrix formation and deposit (Supplemental Figure 16F).
Effects of JQ1 on survival. To determine effects of treatment 
with JQ1 on survival, WT and Myh6-Cre LmnaF/F mice were treated 
with daily subcutaneous injection of either a vehicle (10% DMSO 
and 10% 2-hydroxypropyl-β-cyclodextrin) or JQ1 (20 mg/kg/d) 
starting at P14. A group of untreated littermate mice were included 
as a control. Treatment with JQ1 prolonged median survival of the 
Myh6-Cre LmnaF/F mice from 23 days to 32 days and the maximum 
life span from 28 to 42 days (χ2 = 126.1, P < 0.0001; Figure 8A). 
There were no differences in the survival rates between untreat-
ed mice and Myh6-Cre LmnaF/F mice treated with the vehicle (χ2 = 
1.69, P = 0.19). Likewise, treatment with JQ1 had no effect on the 
survival rate of the WT mice.
Effects of JQ1 on body weight. Treatment with JQ1 had no dis-
cernible effect on body weight in the Myh6-Cre LmnaF/F or WT 
Table 1. Echocardiographic parameters in WT and Myh6-Cre LmnaF/F untreated, vehicle-treated, and JQ-treated mice at 3 weeks of age
WT Myh6-Cre LmnaF/F P value
Groups Untreated Vehicle-treated JQ1-treated Untreated Vehicle-treated JQ1-treated Interaction Treatment Genotype
N 12 10 11 16 11 22
M/F 4/8 3/7 7/4 8/8 7/4 11/11
Age (days) 21.5 ± 1.0 21.1 ± 1.0 21.4 ± 0.7 20.9 ± 1.3 20.6 ± 0.5 21.0 ± 0.5 0.85 0.38 0.02
BW (g) 9.5 ± 2.6 10.0 ± 1.5 8.4 ± 2.6 9.0 ± 0.7 9.5 ± 1.2 8.6 ± 1.2 0.95 0.009 0.26
HR (bpm) 464 ± 52 446 ± 33 436 ± 32 479 ± 77 477 ± 37 492 ± 51 0.40 0.70 0.006
ST (mm) 0.56 ± 0.1 0.55 ± 0.1 0.50 ± 0.1 0.51 ± 0.5 0.47 ± 0.1 0.42 ± 0.1A,B 0.84 0.046 0.003
PWT (mm) 0.60 ± 0.1 0.64 ± 0.1 0.66 ± 0.1 0.48 ± 0.1B,C 0.49 ± 0.1B,C 0.47 ± 0.1A,B,C 0.59 0.44 <0.0001
LVEDD 2.92 ± 0.4 3.05 ± 0.3 2.57 ± 0.6 3.50 ± 0.5A,C 3.78 ± 0.3A,B,C 3.32 ± 0.5C,E 0.86 0.001 <0.0001
LVEDDi (mm/g) 0.32 ± 0.0 0.31 ± 0.1 0.32 ± 0.1 0.39 ± 0.0A,B,C 0.40 ± 0.0A,B,C 0.39 ± 0.1A,B,C 0.85 0.71 <0.0001
LVESD (mm) 1.69 ± 0.3 1.83 ± 0.3 1.45 ± 0.5 3.08 ± 0.6A,B,C 3.39 ± 0.4A,B,C 2.51 ± 0.7A,C,D,E 0.17 <0.0001 <0.0001
LVESDi (mm/g) 0.18 ± 0.0 0.19 ± 0.0 0.18 ± 0.0 0.34 ± 0.1A,B,C 0.36 ± 0.0A,B,C 0.29 ± 0.1A,B,C,E 0.16 0.051 <0.0001
LVFS (%) 42.1 ± 6.7 40.3 ± 4.7 44.5 ± 8.3 12.8 ± 9.0A,B,C 10.7 ± 3.4A,B,C 25.5 ± 9.6A,B,C,D,E 0.004 <0.0001 <0.0001
LVM (mg) 37.5 ± 13.7 41.0 ± 8.2 30.4 ± 11.3 41.7 ± 13.6 45.6 ± 9.5C 33.1 ± 7.3E 0.88 0.0006 0.16
LVMi (mg/g) 3.9 ± 1.2 4.1 ± 0.7 3.6 ± 0.6 4.6 ± 1.3 4.8 ± 0.8 3.9 ± 0.8 0.82 0.07 0.009
χ2 was used to compare the male/female (M/F) distribution. Data were analyzed by 2-way ANOVA followed by Bonferroni’s test for pairwise comparison.  
AP < 0.05 for untreated WT vs. untreated, vehicle-treated, or JQ1-treated Myh6-Cre LmnaF/F. BP < 0.05 for vehicle-treated WT vs. untreated, vehicle-treated, 
or JQ1-treated Myh6-Cre LmnaF/F. CP < 0.05 for JQ1-treated WT vs. untreated, vehicle-treated, or JQ1-treated Myh6-Cre LmnaF/F. DP < 0.05 for untreated 
Myh6-Cre LmnaF/F vs. JQ1-treated Myh6-Cre LmnaF/F. EP < 0.05 for vehicle-treated Myh6-Cre LmnaF/F vs. JQ1-treated Myh6-Cre LmnaF/F. HR, heart rate; 
bpm, beats per minute; ST, interventricular septal thickness; PWT, posterior wall thickness; LVEDD, left ventricular end-diastolic diameter; LVEDDi, LVEDD 
indexed to body weight; LVESD, left ventricular end-systolic diameter; LVESDi, LVESD indexed to body weight; LVFS, left ventricular fractional shortening; 
LVM, left ventricular mass; LVMi, LVM indexed to body weight.
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which was in accord with improved survival in the JQ1-treated 
Myh6-Cre LmnaF/F mice (Supplemental Table 7).
Effects of JQ1 on myocardial fibrosis. Given the marked dysreg-
ulation of EMT signature in the Myh6-Cre LmnaF/F cardiomyo-
tricular arrhythmias, which were also observed in the Myh6-Cre 
LmnaF/F mice (Figure 2B and Supplemental Table 3). Treatment 
with JQ1 significantly reduced the frequency of supraventricular 
arrhythmias, atrioventricular blocks, and ventricular arrhythmias, 
Figure 8. Phenotypic effects of BET bromodomain protein inhibition in Myh6-Cre LmnaF/F mice. (A) Kaplan-Meier survival curves in the untreated (black 
line; n = 34), vehicle-treated (yellow line; n = 12), and JQ1-treated WT (orange line; n = 14), as well as untreated (red line; n = 28), vehicle-treated (blue 
line; n = 14), and JQ1-treated Myh6-Cre LmnaF/F (green line; n = 11), mice. (B) Selected echocardiographic parameters after 1 week of treatment in 3-week-
old untreated (black dots; n = 12), vehicle-treated (yellow dots; n = 10), and JQ1-treated WT (orange dots; n = 11), as well as untreated (red dots; n = 16), 
vehicle-treated (blue dots; n = 11), and JQ1-treated (green dots; n = 22) Myh6-Cre LmnaF/F, mice. P values shown were obtained using 2-way ANOVA and 
Bonferroni’s post hoc test for comparisons; *P < 0.05, †P < 0.01, #P < 0.001, ‡P < 0.0001. PI, P value for interaction; PG, P value for genotype, PRx, P value for 
treatment effect. (C) Expression levels of known markers of cardiac dysfunction, quantified by RT-qPCR, after 1 week of treatment in 3-week-old untreated 
(black dots; n = 4) and JQ1-treated WT (orange dots; n = 5) mice, as well as untreated (red dots; n = 6) and JQ1-treated (green dots; n = 8) Myh6-Cre LmnaF/F 
mice. Because untreated and vehicle-treated mice were indistinguishable, only untreated and JQ1-treated mice were analyzed. P values shown were 
obtained with ordinary 1-way ANOVA or Kruskal-Wallis; *P < 0.05, †P < 0.01, #P < 0.001, ‡P < 0.0001.
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effects of inhibition of BRD4 toward treatment of human patients 
with DCM in laminopathies.
Because LMNA is a ubiquitously expressed protein, mutations 
in the LMNA gene are expected to affect multiple cell types (13, 
29). The ensuing clinical phenotype associated with the LMNA 
mutations is the consequence of changes in multiple cell types. 
Deletion of the Lmna gene exclusively in cardiomyocytes recapit-
ulated several components of LMNA-associated DCM in humans, 
including cardiac dysfunction, arrhythmias, fibrosis, and apopto-
sis. The cardiac phenotype in the Myh6-Cre LmnaF/F mice is not 
distinct from that observed in mice with systemic deletion of Lmna 
or expressing LMNA with missense mutations but perhaps is more 
pronounced (28, 53, 54). The similarities in the findings between 
myocyte-specific and systemic deletion of the Lmna gene signify 
the crucial role of cardiomyocytes in cardiomyopathies result-
ing from mutations in the LMNA gene. However, the beneficial 
effects of treatment with JQ1 might be in part mediated through 
the effects on systemic delivery of JQ1 on other cardiac cell types, 
in addition to its effects on cardiomyocytes.
BRD4 was among the top dysregulated epigenetic factors in 
Myh6-Cre LmnaF/F myocytes. The major function of BRD4 is to 
promote transcription by binding to acetylated histones, tran-
scription factors, and other chromatin-associated proteins, result-
ing in recruitment of positive regulators of gene expression and 
displacement of the negative regulators (55). Consistent with 
this knowledge, transcript levels of 123 of 145 BRD4 target genes 
(85%), collected from 4 public data sets and IPA, were increased in 
Myh6-Cre LmnaF/F myocytes. Furthermore, ChIP-Seq data showed 
enriched recruitment of BRD4 and overall an increased expres-
sion of genes associated with these BRD4 peaks in the Myh6-Cre 
LmnaF/F myocytes, which provided further evidence in support of 
activation of BRD4-mediated transcription. Consequently, multi-
ple lines of evidence of activation of BRD4 in cardiomyocytes set 
the rationale for pharmacological inhibition of BRD4 in Myh6-Cre 
LmnaF/F myocytes. The approach was also in accord with the prom-
inent phenotype of myocardial fibrosis in the Myh6-Cre LmnaF/F 
mice and the well-established role of BRD4 in EMT, as well as 
the emerging role of inhibitors of BRD4 in reversing fibrosis and 
attenuating myocardial dysfunction (39–42).
The beneficial effects of treatment with JQ1 were concordant 
across multiple phenotypes, including prolonged survival, reduced 
cardiac conduction defects and arrhythmias, and improved cardi-
ac function, fibrosis, and apoptosis, which were corroborated by 
complementary methods whenever applicable. Likewise, admin-
istration of JQ1 partially restored dysregulated cardiomyocyte 
transcriptome, particularly transcripts of the genes involved in 
inflammation and those encoding cardiac secretome and their 
upstream regulators, such as the TGF-β1 pathway. Partial resto-
ration of secretome was associated with attenuation of EMT and 
myocardial fibrosis. Similarly, administration of JQ1 attenuated 
myocardial apoptosis, which is likely a phenotype effect of the 
secretome; however, the identity of myocardial cells undergoing 
apoptosis in the Myh6-Cre LmnaF/F hearts could not be ascertained 
by the TUNEL assay. Improvement of cardiac function was likely 
the consequence of effects of JQ1 on myocytes, including secre-
tome, as well as its effects on nonmyocyte cells. The rescue, while 
remarkable for the relatively large effect sizes on all assessed phe-
cytes and in view of the well-established effects of BRD4 in medi-
ating fibrosis in various organs, effects of JQ1 administration on 
myocardial fibrosis were assessed by determination of CVF and 
transcript levels of genes involved in fibrosis (40, 42). CVF com-
prised 8.3% ± 2.6% and 6.6% ± 0.9% of the myocardial area in the 
untreated and vehicle-treated Myh6-Cre LmnaF/F mice, respec-
tively (P < 0.01 compared with WT; Figure 9, A–C). Treatment 
with JQ1 reduced CVF by about 68% (P < 0.0001) in comparison 
with WT and by approximately 60% (P = 0.013) in comparison 
with vehicle-treated Myh6-Cre LmnaF/F mice (Figure 9, A and B). 
Consequently, CVF in JQ1-treated Myh6-Cre LmnaF/F mice was 
similar to that in the WT mice.
To corroborate the findings, transcript levels of 13 genes 
involved in myocardial fibrosis were quantified by RT-qPCR on 
whole-heart RNA extracts. As shown in Figure 9D, treatment 
with JQ1 normalized or reduced transcript levels of 12 of 13 (92%) 
genes in the Myh6-Cre LmnaF/F mouse hearts (Figure 9D). Among 
genes analyzed, only transcript levels of Col6a3 were not different 
among 4 experimental groups (Figure 9D).
Effects of JQ1 on myocardial apoptosis. Given increased apop-
tosis in the myocardium of Myh6-Cre LmnaF/F mice, the effect 
of treatment with JQ1 on myocardial apoptosis was assessed by 
TUNEL assay and transcript levels of the molecular markers of 
apoptosis. The number of TUNEL-positive cells was increased 
markedly (about 7-fold) in the myocardium of Myh6-Cre LmnaF/F 
mice at 3 weeks of age (Figure 10, A and B). Treatment with 
JQ1 was associated with a 50% reduction in the number of 
TUNEL-positive cells in the myocardium of Myh6-Cre LmnaF/F 
mice as compared with untreated or vehicle-treated mice (P < 
0.009 and P < 0.002, respectively).
To corroborate the findings, transcript levels of 9 markers 
of apoptosis were quantified by RT-qPCR on whole-heart RNA 
extracts in the experimental groups. Transcript levels of Bcl2, Bnip3, 
Bbc2, and Bcl2l1 were fully rescued (not different from the WT), 
whereas that of Gadd45b remained increased in the myocardium 
of Myh6-Cre LmnaF/F (Figure 10C). Transcript levels of Gadd45a 
and Tnfsf10, which were reduced in the Myh6-Cre LmnaF/F myocar-
dium, did not change upon treatment with JQ1 (Figure 10C). Final-
ly, treatment with JQ1 had no significant effect on transcript levels 
of Gadd45g and Bax, which were unaltered in the myocardium of 
Myh6-Cre LmnaF/F mice (Figure 10C).
Discussion
We report that genetic deletion of the Lmna gene exclusively in 
cardiomyocytes led to a dose-dependent cardiac dilatation and 
dysfunction; cardiac arrhythmias, including conduction defects 
and ventricular arrhythmias; myocardial fibrosis; and apoptosis; 
and resulted in total mortality within 4 weeks in the homozygous 
and 15 months in the heterozygous mice. Transcriptomic analy-
sis identified dysregulation of a dozen transcriptional regulators, 
including the epigenetic reader BRD4, which was activated in the 
Lmna-null cardiomyocytes. Treatment of Lmna-deficient mice 
with JQ1, a well-characterized and specific inhibitor of the BET 
bromodomain proteins, prolonged survival and improved cardiac 
function, cardiac arrhythmias, myocardial fibrosis, and apopto-
sis (44). These findings in a genetically defined mouse model of 
LMNA-DCM set the stage for advancing the findings on beneficial 
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Figure 9. Effect of BET bromodomain protein inhibition on myocardial fibrosis in the Myh6-Cre LmnaF/F mice. (A and B) Representative Masson’s 
trichrome–stained (top panels) and Picrosirius red–stained (bottom panels) myocardial sections after 1 week of treatment in 3-week-old untreated, 
vehicle, and JQ1-treated WT and Myh6-Cre LmnaF/F mice. (C) Corresponding quantitative data showing the percentage of CVF in myocardial sections 
in untreated (black dots; n = 5), vehicle-treated (yellow dots; n = 3), and JQ1-treated WT (orange dots; n = 3), as well as untreated (red dots; n = 7), 
vehicle-treated (blue dots; n = 3), and JQ1-treated (green dots; n = 6) Myh6-Cre LmnaF/F, mice. P values were calculated using 2-way ANOVA and Tukey’s 
post hoc test for comparisons; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. (D) Transcript levels of selected BRD4 target genes involved in 
fibrosis in the heart as quantified by RT-qPCR in untreated (black dots; n = 4) and JQ1-treated (orange dots; n = 5) WT mice, as well as untreated (red 
dots; n = 6) and JQ1-treated (green; n = 8) Myh6-Cre LmnaF/F mice. P values shown were obtained with ordinary 1-way ANOVA or Kruskal-Wallis; *P < 
0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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Figure 10. Effect of BET bromodomain protein inhibition on myocardial apoptosis in the Myh6-Cre LmnaF/F mice. (A) Representative TUNEL-stained thin 
myocardial sections in 3-week-old untreated, vehicle-treated, and JQ1-treated WT mice along with untreated, vehicle-treated, and JQ1-treated Myh6-Cre 
LmnaF/F mouse hearts. Nuclei were counterstained with DAPI. (B) Corresponding quantitative data showing percentage of TUNEL-labeled nuclei in myo-
cardial sections in untreated (black dots; n = 6), vehicle-treated (yellow dots; n = 3), and JQ1-treated (orange dots; n = 3) WT and untreated (red dots; n = 
5), vehicle-treated (blue dots; n = 7), and JQ1-treated (green dots; n = 6) Myh6-Cre LmnaF/F mouse hearts. P values were calculated using 2-way ANOVA and 
Tukey’s post hoc test for comparisons; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. (C) Transcript levels of selected BRD4 target genes involved 
in apoptosis, as quantified by RT-qPCR, are depicted in 3-week-old untreated (black dots; n = 4) and JQ1-treated (orange dots; n = 5) WT mice, and in 
untreated (red dots; n = 6) and JQ1-treated (green dots; n = 8) Myh6-Cre LmnaF/F mouse hearts. P values shown were obtained with ordinary 1-way ANOVA 
or Kruskal-Wallis; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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therapies for LMNA-DCM, inhibition of BET bromodomain, with 
specific and relatively safe drugs, could emerge as an effective ther-
apy that targets a specific pathogenic pathway in LMNA-DCM.
Methods
Detailed methods are provided in Supplemental Methods.
Mouse models. Myh6-Cre, Myh6-Cre LmnaW/F, and Myh6-Cre LmnaF/F 
mice were generated per conventional methods (34, 35). Oligonucle-
otide primers used in PCR reactions are listed in Supplemental Table 8.
Survival. Survival was analyzed by construction of Kaplan-Meier 
survival plots.
Echocardiography and electrocardiography. Cardiac size and func-
tion were assessed in age- and sex-matched mice at 2 weeks, 3 weeks, 
and 10 months by echocardiography, as published (21, 28, 59). Indi-
ces of cardiac size and function were measured in 5–6 cardiac cycles. 
Left ventricular fractional shortening and mass were calculated from 
the measured indices.
Needle electrodes were placed subcutaneously and connected to 
an ECG recording unit to obtain surface ECG.
Isolation of cardiomyocytes. Cardiomyocytes were isolated by col-
lagenase perfusion of the myocardium, as published (28).
Histology. Myocardial fibrosis was quantified by determination of 
CVF in myocardial sections as published (28, 59, 60).
Immunoblotting and immunofluorescence. Expression levels of the 
proteins of interest were detected and quantified by immunoblotting, 
as published (21, 59). Immunofluorescence was performed to detect 
expression and localization of LMNA and PCM1 proteins, using spe-
cific antibodies, as published (21, 59, 60). A detailed list of antibodies 
used is provided in Supplemental Table 8.
Detection of apoptosis. Apoptosis was detected by nick-end label-
ing of DNA with the TUNEL assay, as previously described (21, 59, 
60). Percentage of TUNEL-positive nuclei was determined in 6400 to 
16,500 DAPI-positive nuclei per mouse.
Quantitative real-time PCR. Transcript levels of selected genes 
were determined by RT-qPCR, using specific TaqMan gene expres-
sion assays or SYBR Green specific primers, and normalized to glycer-
aldehyde-3-phosphate dehydrogenase (Gapdh) mRNA levels, as pub-
lished (21, 59). TaqMan probes and SYBR Green primers are detailed 
in Supplemental Table 8.
RNA-Seq. RNA-Seq was performed on ribosome-depleted RNA 
extracted from the hearts of 2-week-old WT and Myh6-Cre LmnaF/F as 
well as 3-week-old WT, vehicle-treated, and JQ1-treated mice, as pub-
lished (21, 59, 60). Samples with an RNA integrity number (RIN) read-
out of more than 8 were used for library preparation and sequencing to 
generate 75 or 100 bp runs. DEGs were identified using edgeR, voom, 
and DESeq2 following RUV (remove unwanted variation) adjust-
ment and annotated using the GENCODE gene model (https://www. 
gencodegenes.org/mouse) (61–64). Pathway analysis was performed 
by Gene Set Enrichment Analysis (GSEA, version 2.2.3, http://software. 
broadinstitute.org/gsea) using the ranked gene list (65). Activation of 
BRD4 was further validated against BRD4 target genes reported in 
4 independent public data sets (39, 41). DEGs encoding the secreted 
proteins were obtained as published (59).
ChIP-Seq. Myocytes were isolated, chromatin was cross-linked 
with 1% formaldehyde, nuclei were extracted and homogenized in a 
nuclear lysis buffer, and chromatin was sheared by sonication, as pub-
lished (31). After overnight immunoprecipitation with an anti-BRD4 
notypes, was incomplete. Treatment with JQ1 delayed premature 
death, improved cardiac function, and reduced arrhythmias but 
did not fully abrogate the LMNA-DCM phenotype. The incom-
pleteness of the rescue likely had multiple reasons, including the 
multifarious nature of the pathways involved in the pathogenesis of 
LMNA-DCM, such as activation of KDM5A, MAP4K4, and TP53, 
as well as suppression of RB1 and INSR transcriptional regulators, 
among others, as well as the study design pertaining to dose, tim-
ing, and route of administration of JQ1. Several of the upstream 
regulatory pathways predicted to be dysregulated in the Myh6-Cre 
LmnaF/F myocytes, including TP53, have been previously implicat-
ed in the pathogenesis of LMNA-associated DCM in humans and 
mouse models (21, 28). However, administration of JQ1 rescues 
only a fraction of the dysregulated pathways and a few of them only 
partially, which in part may explain incomplete phenotypic rescue. 
The complexity of the LMNA-DCM phenotype would necessitate 
targeting of multiple pathogenic pathways for a superior thera-
peutic gain. This notion is in accord with the current therapeutic 
practice in treatment of complex phenotypes, such as heart failure, 
wherein the effect size of each therapeutic modality, while signifi-
cant, is relatively modest, necessitating polypharmacy.
The findings in LMNA-DCM mice are in agreement with pre-
vious data on the profibrotic effects of BRD4 and the beneficial 
effects of JQ1, a first-in-class paninhibitor of BET bromodomain 
proteins, on attenuation of myocardial fibrosis and cardiac dys-
function in pressure overload and myocardial infarction mouse 
models (39, 41). Suppression of cardiac arrhythmias upon treat-
ment with JQ1 is remarkable and, to our knowledge, a novel find-
ing. Several mechanisms are likely to be involved in the beneficial 
effects of JQ1 in heart failure and profibrotic conditions. The core 
mechanism likely pertains to competitive displacement of BRD 
proteins by JQ1 from acetyl-lysine recognition motif on histones, 
and the consequent suppression of aberrant gene expression (44).
The molecular mechanism(s) responsible for activation of 
BRD4 in the Myh6-Cre LmnaF/F mouse heart is unknown. Coim-
munoprecipitation studies do not show an interaction between the 
LMNA and BRD4 proteins. In addition, transcript levels of Brd4 
were not significantly changed in Myh6-Cre LmnaF/F myocytes, 
suggesting a post-transcriptional mechanism(s) for activation of 
BRD4, such as hyperphosphorylation, which is typically mediated 
by CDK9 (56). Previous data suggest that activation of BRD4 in 
cardiac fibroblasts is mediated, in part, through p38 MAP kinase 
(MAPK14) and TGF-β1 pathways (42). The activation leads to 
recruitment of BRD4 to enhancers provoking expression of proin-
flammatory and profibrotic genes through a yet-to-be-defined 
mechanism(s) (42). It is noteworthy that TGF-β1 and MAP4K4, 
the latter known to regulate p38, were among the top activated 
transcriptional coregulators in Myh6-Cre LmnaF/F myocytes (Fig-
ure 3C and refs. 57, 58). Several alternative mechanisms might also 
be involved, such as chromatin conformational and epigenetic 
changes in the absence of LMNA, which might lead to activation 
of BRD4 in cardiomyocytes.
The findings showing beneficial effects of treatment with JQ1 in 
Myh6-Cre LmnaF/F mice serve as proof-of-principle data that set the 
stage for additional preclinical studies in heterozygous Lmna-knock-
out mice and pilot clinical studies in humans to advance the utility 
of targeting BRD4 in LMNA-DCM. Given the paucity of specific 
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sented as the median values and compared by Kolmogorov-Smirnov, 
Kruskal-Wallis, or Mann-Whitney test followed by Dunn’s test cor-
rection for multiple comparison. Survival rates were analyzed by con-
struction of Kaplan-Meier survival plots and comparison of the surviv-
al rate by log-rank (Mantel-Cox) test. A q value of less than 0.05 and a 
P value of less than 0.05 were considered significant.
Study approval. The animal care and use committee of the Univer-
sity of Texas Health Science Center approved the mouse studies.
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antibody, the complexes were immunoprecipitated. The chromatin 
elution was treated with RNase A and proteinase K, and the DNA was 
extracted using phenol/chloroform and ethanol precipitation. The 
protocol was also followed for the DNA sample used for sequencing as 
well as ChIP-PCR. Libraries were prepared, and single reads of 50 bp 
length were sequenced.
Sequencing of BRD4 ChIP-Seq libraries yielded 36 to 65 million 
single-end reads. Reads were aligned to the mouse genome (mm10 
release) by Bowtie version 2.3.4.3, and uniquely mapping reads were 
analyzed. ChIP-Seq peaks were called using MACS2 from Galaxy 
(version 2.1.1) (66). Enriched regions were intersected using Multiple 
Intersect tools (Galaxy version 2.27.1), and regions present in at least 
2 samples per genotype were considered BRD4-bound regions (q < 
0.05). BRD4-bound regions that were present in the Myh6-Cre LmnaF/F 
but absent in the WT samples were considered as gain of peak (GoP) 
and those that were unique to WT as loss of peak (LoP). Plots show-
ing gene density versus expression were generated using the density 
plots and the sort map function in R (https://cran.r-project.org/) and 
EaSeq (http://easeq.net) (67). Data were deposited in the NCBI’s Gene 
Expression Omnibus database (GEO GSE142129). ChIP-Seq signal 
and genomic localization were visualized using Integrative Genom-
ics Viewer (IGV). Genomic locations showing BRD4 enrichment at its 
putative targets were obtained from IGV.
ChIP-qPCR. The ChIP-Seq findings were tested for validation in 
an independent set of ChIP experiment using an anti-BRD4 antibody 
on cardiomyocyte chromatin extracted from the WT and Mhy6-Cre 
LmnaF/F mice, as described above. Genomic regions showing enrich-
ment for the BRD4 recruitment were visualized using IGV (68). The 
sequences flanking the enriched regions were used to design oligonu-
cleotide primers, and qPCR was performed to determine enrichment 
of the BRD4 recruitment in the WT and Mhy6-Cre LmnaF/F samples.
Statistics. Normality of data distribution was assessed by Shap-
iro-Wilk test. Data that followed a Gaussian distribution pattern were 
presented as mean ± SD and compared using unpaired t test, ordinary 
1-way ANOVA, or 2-way ANOVA, followed by Tukey’s or Bonferroni’s 
multiple-comparisons test, as appropriate. Otherwise, data were pre-
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